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68.9% acute coronary syndromes (49.4% Non-STEMI and 19.5%
STEMI). 46% of patients were diabetic. 48.3% of lesions were bi-
furcations, 17.2% diffuse and 52.8% type B2/C. Mean vessel diameter
and length were 2.43  0.35 mm and 16.03  5.6 mm, respectively. 77
% of the lesions were treated with PEB, 19.5% with PEB and BMS and
3.4% with PEB and DES. There were no signiﬁcant differences
regarding baseline characteristics of these three groups neither in the
MACE rate after a long-term follow-up (p¼0.5). During follow-up, 6
patients died (1 cardiovascular and 5 non-cardiovascular deaths) and a
TLR rate of 2.3% was observed. Two cases of non-fatal myocardial
infarction (2.3%) and no cases of thrombosis were observed, imme-
diately after the procedure nor during follow-up. 16.1% of patients had
angiographic follow-up. We did not observe a higher need for addi-
tional stent after PEB in complex lesions such as diffuse lesions
(p¼0.7) and bifurcations (p¼0.7). However a higher MACE rate at 5
years was observed in bifurcations and ostial lesions.
CONCLUSIONS Percutaneous interventions of “De Novo” coronary
lesions with Sequent Please PEB offers very favorable results at a
very long-term follow up. There was not a higher need for additional
stent in cases of diffuse and bifurcated lesions.
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BACKGROUND Drug eluting balloons currently constitute one of the
therapeutic tools used in percutaneous coronary intervention (PCI) of
both stent restenosis and “De Novo” coronary lesions, mainly in bi-
furcations and small vessels. Diabetic patients represent an unfavor-
able subgroup because of their higher restenosis and adverse events
rates. Nowadays, the results at a very long-term follow up are unclear
in this subset of patients. The main objective of this study was to
evaluate the efﬁcacy and safety of second-generation Sequent Please
paclitaxel eluting balloon (PEB) at 6 years in diabetics.
METHODS We prospectively included 111 consecutive diabetic pa-
tients (6912 years, 64% male) with 111 lesions (de novo or restenosis)
treated with PEB between March 2009 and January 2014. We evalu-
ated the presence of major cardiac events (MACE) after a prolonged
clinical follow-up (median 47 months): death, nonfatal myocardial
infarction, target lesion revascularization (TLR) and thrombosis.
RESULTS 44.2% of patients had stable coronary artery disease and
55.8% acute coronary syndromes (45% Non-STEMI and 10.8% STEMI).
20.7% of lesions were bifurcations. Of the 111 lesions, 36.1% were “De
Novo” lesions and 63.9% restenosis [37.8% restenosis of bare metal
stent (BMS) and 26.1% of drug-eluting stents (DES)]. 88.3% of the le-
sions were treated with PEB, 8.1% with PEB and BMS and 3.6% with
PEB and DES. There were no signiﬁcant differences regarding baseline
characteristics of these three groups neither in the MACE rate after a
long-term follow-up (p¼0.8). During follow-up, 9 patients died (3
cardiovascular and 6 non-cardiovascular deaths), and a TLR rate of
3.6% and two non-fatal myocardial infarction rate of 1.8% were
observed. No cases of thrombosis were observed, immediately after
the procedure nor during follow-up. 19.8% of patients had an angio-
graphic follow-up. Bifurcated lesions presented a higher rate of
dissection after PEB (p¼0.016) and a higher need of additional stent
(p¼0.025).
CONCLUSIONS In diabetic patients, percutaneous coronary inter-
vention of de novo coronary lesions and in-stent restenosis (both of
BMS and DES) with Sequent Please PEB provide very favorable re-
sults at a very long-term follow up. Bifurcated lesions presented a
higher rate of dissection after PEB and a higher need of additional
stent.
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BACKGROUND There has been much interest in the use of paclitaxel
coated balloon (PCB) only angioplasty in de novo coronary lesions. In
certain clinical situations such as bifurcation, recoil or major dissec-
tion after PCB deployment an additional stent may be implanted to
support vessel patency. The consensus opinion is to use a bare metal
stent (BMS) instead of a drug eluting stent to cover the PCB treated
segment. This may avoid the unknown effect of combining paclitaxel
with a limus agent. We designed a porcine model to compare the
angiographic and optical coherence tomography (OCT) ﬁndings of
implanting an everolimus eluting stent (EES) in the same segment of
the coronary artery pre-treated with a PCB (paccocath as carrier) with
EES alone and PCB plus BMS.
METHODS 7 female swine averaging 46.02.4 kg were studied. Under
general anesthetic, the 3 coronary arteries of each animal were randomly
implantedwith 1. PCB (3.0 by 15mm) followed by EES (3.0 by 8mm); 2. PCB
(3.0 by 15mm) followed by BMS (3.0 by 8mm) and 3. EES (3.0 by 8mm)
alone. Quantitative coronary angiography (QCA) and OCTwere carried out
post implantation. QCA and OCT were repeated after 281 days.
RESULTS All arteries remained patent and demonstrated no sign of
thrombus formation on angiogramorOCT. Thewas nodifference in lumen
loss at 1 month between the 3 treatment groups (0.520.36mm,
0.450.44mm and 0.300.24mm for EES, PCBþEES and PCBþBMS
respectively, p¼0.54). There was no difference in diameter stenosis at 1
month (8.7111.88%, 4.1412.97% and 4.807.65% for EES, PCBþEES and
PCBþBMS respectively, p¼0.71). The mean endothelial area measured by
OCT at 1 month were 1.580.83mm2, 0.950.19mm2 and 0.970.23mm2
for EES, PCBþEES and PCBþBMS respectively, p¼0.064.
CONCLUSIONS The combination of PCB with EES appeared to be safe
and effective compared to EES alone. There is a trend to suggest the
combination of PCB with EES may be more effective in suppressing
neointimal hyperplasia than using EES as observed in the lower
endothelial area measurement. Using EES to bail out suboptimal PCB
therapy appeared to be safe and effective in the porcine model.
Further histological analysis and larger cohort may provide more in-
formation on this treatment strategy.
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